Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
UroGen Pharma Ltd. (URGN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments"
07/27/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, ...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Form of July 2023 Pre-Funded Warrant",
"Securities Purchase Agreement, by and among UroGen Pharma Ltd. and the Purchasers named therein",
"UroGen Announces $120 Million Private Placement of Ordinary Shares PRINCETON, N.J.—July 27, 2023— UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has entered into a definitive securities purchase agreement in connection with a private placement to selected institutional and accredited investors. RA Capital Management L.P. and Great Point Partners LLC led the Private Placement, which also included Acorn Bioventures, Monograph Capital and Horton Capital Partners Fund, LP. UroGen expects to receive gross proceeds of approximately $120 million, before deducting placement agent commissions and other offering expenses. UroGen intends to use the net proceeds of the Private ...",
"Company Presentation",
"Trial Results Slides"
07/25/2023 8-K Quarterly results
05/11/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments"
03/22/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments",
"Excerpt of transcript from conference call held on March 16, 2023"
11/10/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments"
11/09/2022 8-K Quarterly results
10/21/2022 8-K Quarterly results
09/12/2022 8-K Appointed a new director
08/11/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/21/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Employment Agreement between the Company and Dong Kim",
"UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments"
03/08/2022 8-K Quarterly results
11/15/2021 8-K Quarterly results
Docs: "UroGen Pharma Reports Third Quarter 2021 Financial Results and Recent Corporate Developments"
11/10/2021 8-K Other Events  Interactive Data
09/13/2021 8-K Quarterly results
08/04/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"UroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate Developments"
07/14/2021 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"UroGen Pharma Reports Strong Preliminary Jelmyto ® Sales for Second Quarter 2021"
06/08/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
03/18/2021 8-K Quarterly results
03/18/2021 8-K Quarterly results
01/13/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
12/03/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
11/17/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
11/09/2020 8-K Quarterly results
Docs: "UroGen Pharma Reports Third Quarter 2020 Financial Results and Recent Corporate Developments Top-line Results from UGN-102 OPTIMA II Phase 2b Trial Expected by Year End 2020; On Track to Initiate Phase 3 ATLAS Trial by Year End"
08/27/2020 8-K Quarterly results
08/10/2020 8-K Quarterly results
06/10/2020 8-K Changes in Registrant's Certifying Accountant, Departure of Directors or Certain Officers; Election of Directors; Appointment...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"UroGen Pharma Ltd. 2017 Equity Incentive Plan, as amended",
"Letter from Kesselman & Kesselman, Certified Public Accountants, an independent registered public accounting firm and a member firm of PricewaterhouseCoopers International Limited"
05/15/2020 8-K Quarterly results
03/23/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Separation Agreement between the Company and Stephen Mullennix"
12/20/2019 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy